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Abstract
Backgrounds/Aims: Pericyte loss, vasoregression
and neuroglial activation are characteristic changes
in incipient diabetic retinopathy. In this study, the ef-
fect of the antioxidant and antiglycating dipeptide
carnosine was studied on the development of experi-
mental diabetic retinopathy. Materials/Methods: STZ-
induced diabetic Wistar rats were orally treated with
carnosine (1g/kg body weight/day). Retinal vascular
damage was assessed by quantitative morphometry.
Retinal protein extracts were analyzed for markers of
oxidative stress, AGE-formation, activation of the hex-
osamine pathway and changes in the expression of
Ang-2, VEGF and heat shock proteins Hsp27 and
HO-1. Glial cell activation was analyzed using West-
ern blot analysis and immunofluorescence of GFAP
expression and retinal neuronal damage was
histologically examined. Results: Oral carnosine treat-
ment prevented retinal vascular damage after 6
months of experimental hyperglycemia. The protec-
tion was not caused by ROS- or AGE-inhibition, but
associated with a significant induction of Hsp27 in ac-
tivated glial cells and normalization of increased Ang-
2 levels in diabetic retinas. A significant reduction of
photoreceptors in retinas of carnosine treated ani-
mals was noted. Conclusion: Oral carnosine treat-
ment protects retinal capillary cells in experimental
diabetic retinopathy, independent of its biochemical
function. The vasoprotective effect of carnosine might
be mediated by the induction of protective Hsp27 in
activated glial cells and normalization of
hyperglycemia-induced Ang-2.
Introduction
Diabetic retinopathy (DR) is the most prevalent mi-
crovascular complication of diabetes and a leading cause
of blindness in people at working age [1]. Incipient stages
are characterized by progressive vasoregression, initiated
by loss of retinal pericytes and endothelial degeneration.
Resulting basement membrane tubes are free of cell nu-
clei and no longer perfused leading to focal tissue hy-
poxia [2]. Subsequent endothelial cell proliferation results
in microaneurysm formation and hypercellularity of reti-
nal vessels. In parallel, retinal capillaries show a break-
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down of the blood-retinal-barrier [3, 4]. Resulting from
increased mitochondrial oxidative stress, several down-
stream mechanisms have been proposed to mediate
hyperglycemia-induced cell damage, including increased
flux through the hexosamine pathway, activation of PKC-
pathway and increased formation of AGEs [5]. Experi-
mental inhibitors targeting these pathways have been
tested in animals. Of note, some efficiently inhibited the
formation of acellular capillaries as the most predictive
retinal lesion whereas others were either not successful
in preventing DR or work only in combination with other
compounds [6-10].
Carnosine, a naturally occurring dipeptide primarily
produced in skeletal muscle and the central nervous sys-
tem acts as both, a scavenger of ROS and an inhibitor of
AGE production [11, 12]. Carnosine is synthesized from
E-alanine and histidine and is specifically degraded by
serum-carnosinase (CN-1). Growing evidence suggests
a role of the carnosine-carnosinase system in the
pathogenesis of diabetic complications [13]. As recently
demonstrated by Janssen et al., CN-1 is involved in the
susceptibility of diabetic patients to develop diabetic ne-
phropathy [14]. Patients with a genotype that determines
low secretion efficiency and subsequent low enzyme
activity in blood were protected from DN, suggesting a
genetical determination of kidney protection in diabetic
patients. Furthermore, the data indicate that the substrate
of CN-1, carnosine might be beneficial in relation to dia-
betic complications. Experimentally, it has been demon-
strated that carnosine reduces lipid oxidation in kidneys
and inhibits glucose-induced proliferation of mesangial cell
[15, 16]. Furthermore, accumulation of extracellular ma-
trix and upregulation of profibrotic TGF-E is preventable
by carnosine in cultured human podocytes and mesangial
cells, suggesting that carnosine is a protective factor in
diabetic nephropathy [14]. Moreover, carnosine might also
be involved in other diabetic complications. In diabetic
db/db and Balb/ca mice, carnosine substitution improved
glucose metabolism and in STZ-diabetic mice it delayed
the onset of diabetic neuropathy [17, 18]. A protective
potential of carnosine has been demonstrated in diabetic
cataractogenesis. Carnosine eye drops protected from
hyperglycemia-induced cataract formation in STZ-induced
diabetic rats. Thus, it has been suggested that carnosine
is a potent agent for therapy of senile cataracts and dia-
betic ocular complications [19, 20].
However, the therapeutic potential of carnosine in
the treatment of DR has not been tested yet. Increased
oxidative stress, based on hyperglycemia-induced mito-
chondrial overproduction of reactive oxygen species, has
been identified as the common denominator of vascular
damage. Glial cell activation and neuronal cell death are
implicated in the development of DR [3, 21, 22]. Carno-
sine is one of the most abundant antioxidants in the brain,
and in the retina, it is present in retinal neurons and Mueller
glia [23-27]. As the dipeptide inhibits the synthesis of
microglial inflammatory and oxidative stress mediators,
its implication in the prevention of neuronal apoptotic cell
death is conceivable. As a further beneficial action, car-
nosine induces the expression of heat shock proteins in
mucosal cells and protects against excitotoxic cell death
independently of its effects on reactive oxygen species
in brain neurons [28-31]. Hsps are upregulated in acti-
vated neuroglia of diabetic animals and Hsp-inducers such
as bimoclomol have demonstrated preventive effects in
experimental diabetic neuropathy and in early retinal dam-
age in diabetic animals [32, 33].
In the light of these data, it is conceivable that car-
nosine has protective potentials on DR. We assessed
vascular damage, hyperglycemia-induced biochemical
changes, changes in the expression of VEGF, Ang-2 and
Hsp, glial cell activation and neuronal damage in retinas
of STZ-induced diabetic rats with oral carnosine treat-
ment.
Materials and Methods
Animals, diabetes induction and carnosine treatment
The care and experimental use of all animals in the study
were in accordance with institutional guidelines and in compli-
ance with the Association for Research in Vision and Ophthal-
mology (ARVO) statement. Male Wistar rats were purchased
(Harlan Winkelmann GmbH, Borchen, Germany) and housed in
a 12h light/dark cycle with free access to food and drinking
water. Animals were randomly divided into a non-diabetic (NC)
and a diabetic group (DC). Rats of the diabetic group were
rendered diabetic by i.v. injection of STZ, (45 mg/kg body weight
diluted in citrate buffer, pH 4.5 (Roche, Mannheim, Germany)).
Animals were considered diabetic if blood glucose levels re-
mained over 250 mg/dl. Animals of the diabetic group were
randomly selected to receive carnosine in the daily water (1
gram carnosine/kilogram body weight/day (Flamma S.p.a.,
Chignolo d’Isola, Italy)) beginning one week after diabetes
induction. Blood glucose level and body weight were moni-
tored regularly (ACCU Check Comfort, Nr.63877, Roche Diag-
nostics, Mannheim, Germany). Eyes of each individual animal
of all groups were inspected for cataract formation by two in-
dependent investigators after 6 weeks, 3 months and 6 months
of hyperglycemia. Lenticular opacity was graded macroscopi-
cally as clear or dense. After sacrifice at 2 weeks, 3 and 6 months
of hyperglycemia, respectively, eyes were obtained from deeply
anesthetized animals and immediately frozen at -80°C until fur-
ther analysis or fixed in 4% formalin. Blood samples were col-
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lected for the determination of glycated haemoglobin concen-
tration by affinity chromatography at the end of the study
(MicromatII™; Bio-Rad Laboratories GmbH, Munich, Ger-
many). After two weeks of treatment, carnosine concentration
in retinal tissue was measured fluorometically by high-perform-
ance liquid chromatography (HPLC) as previously described
[14, 34].
Retinal digest-preparations and quantitative retinal
morphometry
We performed quantitative retinal morphometry in retinal
digest preparations to evaluate capillary endothelial cell and
pericyte numbers. In brief, eyes were fixed in 4% formaldehyde
for at least 1 day. Next, retinas were isolated and incubated in
distilled water at 37°C for 30min. Then, retinas were treated
with a digestion solution (3% trypsin dissolved in 0.2M Tris-
HCL (pH7.4) solution for 2-3 hours at 37°C). After washing
under a dissection microscope the isolated retinal vasculature
was dried on glass slides and stained with periodic acid-Schiff
reagent and Meyer’s hematoxylin (1:2, Merck, Darmstadt, Ger-
many). Endothelial cell and pericyte numbers were quantified
in 10 randomly selected areas (magnification 400x) in a circular
area of the middle third of 6 retinas per group, using an image
analyzing system (CUE-2; Olympus Opticals, Hamburg, Ger-
many). Cell numbers were relativized to the retinal capillary
area (numbers of cells per mm2 of capillary area) of each quan-
tified field by software (AnalySIS®, Soft Imaging System
GmbH, Muenster, Germany).
Biochemical changes, growth factors and heat-shock
proteins
Retinal proteins were extracted in a lysis buffer contain-





0.5 % deoxycholic acid, 0.1 % SDS, 1% Triton-X-100 and a
cocktail of protein inhibitors (Complete Mini tablets, Roche
Diagnostics, USA). The lysates were homogenized by tritura-
tion with 20-, 22-, 25- and 27-gauge needles and insoluble ma-
terial was removed by centrifugation at 10000 rpm/min for 10
minutes at 4° C. Supernatants were collected and protein con-
centrations were measured by Bradford assay (Bio-Rad Labo-
ratories GmbH, Munich, Germany). Prior to separation on 10%
SDS PAGE gel, protein extracts (10-30 μg) were boiled for 5min
at 100° C in 5 % beta-mercaptoethanol containing Laemmli
buffer (Bio-Rad Laboratories GmbH, Munich, Germany). After
separation, proteins were electrophoretically transferred to a
PVDF membrane (Roche, Mannheim, Germany) using a semi-
dry blotting system at ~ 0.7 mA/cm2 for 1.5hrs. Membranes
were incubated with 5 % non-fat dry milk dissolved in TBS
containing 0.1% Tween 20 (Sigma-Aldrich, Steinheim, Germany)
for 1 h at room temperature to block unspecific binding and
then incubated with primary antibodies overnight at 4°C: mouse
monoclonal NT (0.8 μg/ml in TBS/T, ALX-804-204, Alexis®
Biochemicals, Axxora Deutschland GmbH, Germany), MG-H1
(1:2000 in 5% milk in TBS/T, [35]), mouse monoclonal O-Linked
N-Acetylglucosamine (1:2000 in 5% milk in TBS/T, ab2739,
Abcam, Cambridge, UK), goat polyclonal Ang-2 (1:500 in TBS/
T, sc-7017, Santa Cruz Biotechnology, Heidelberg, Germany),
monoclonal anti-rat VEGF (1:250 in TBS/T, MAB564, R&D Sys-
tems, Wiesbaden, Germany), goat polyclonal Hsp27 (1:500 in
5% milk in TBS/T, sc-1048, Santa Cruz Biotechnology) and goat
polyclonal GFAP (1:500 in 5% milk in TBS/T, sc-6170, Santa
Cruz Biotechnology). The blots were incubated with appropri-
ate horseradish peroxidase (HRP)-conjugated secondary anti-
body (DAKO Cytomation, Hamburg, Germany) diluted in 5%
milk/TBS/Tween 20 solution for 1hr at room temperature. Anti-
body binding was visualized by enhanced chemiluminescence
(Perkin Elmer, Boston, MA, USA). For loading control, mem-
branes were stripped and re-probed with antibodies against
GAPDH (GAPDH antibody – Loading Control, ab9484, Abcam).
Intensity of specific bands was measured by densitometry
using the ImageJ 1.36b software and means of the absolute
values of each group were expressed relative to non-diabetic
controls.
Levels of HO-1 in retinal lysates were measured by using
ELISA kit systems (StressXpress HO-1 (Rat) ELISA kit, EKS-
810A, Stressgen Bioreagents, Kampenhout, Belgium). For the
ELISA, half frozen retinas were homogenized by trituration in
150 μl PBS. The homogenates were frozen at -20 °C over night
and after centrifugation at 10000 rpm/min, the supernatant was
collected and protein concentration was measured by Brad-
ford assay (Bio-Rad Laboratories GmbH, Munich, Germany).
Retinal lysates were further diluted 1:5 and directly used in the
ELISA according to manufacturer’s instructions. Recombinant
rat HO-1 served as standard and the absorbance of all samples
were analyzed in duplicate at 450 nm wavelength with a
microplate reader.
Immunoflurescence staining of GFAP and Hsp27
3 micrometer paraffin sections were deparaffinized, rehy-
drated, microwaved (2x 5min at 500 Watt (W) and 2x 5min at 270
W) in citrate buffer (Glycerolgelatine and Di-sodium hydrogen
phosphate dihydrate), and then treated with 1 % BSA and 0.5
% Triton-100 in PBS for 30min at room temperature. Subse-
quently, sections were incubated with rabbit anti GFAP (sc-
6170, Santa Cruz biotechnology, Inc., Heidelberg, Germany) at
a concentration of 1:200 in PBS (DAKO Cytomation, Hamburg,
Germany) at 4°C overnight. After washing in PBS, sections
were incubated with swine anti rabbit secondary antibody con-
jugated with TRITC at room temperature for 1 hour (DAKO
Cytomation). For double staining, sections were further treated
with antibodies against Hsp27 over night at 4°C (1:50 in PBS,
sc-1048, Santa Cruz Biotechnology, Heidelberg, Germany), fol-
lowed by appropriate secondary FITC-coupled antibodies
(Dako Cytomation). After washes, sections were covered with
50 % glycerol and stainings were visualized with a fluores-
cence microscope (Leica Microsystems GmbH, Wetzlar, Ger-
many).
Histological examination of retinal paraffin sections
Eyes fixed in 4% formalin over night were embedded in
paraffin. 3-micrometer vertical sections around optic nerves
were selected to be dewaxed and rehydrated, then stained with
Periodic Acid Schiff’s (PAS) and hematoxylin according to
standard histological staining protocols. Analysis of number
of cells in retinal nuclear layers was performed at the inner
border of peripheral 1/3 retina by using a microscope (Leica
Carnosine in Experimental Diabetic Retinopathy Cell Physiol Biochem 2011;28:125-136
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DM RBE, Bensheim, Germany) equipped with an analysis pro-
gram (Leica IM50, Herrbrugg, Switzerland). Four images of each
retina were taken for cell number quantification of the ganglion
cell layer (GCL), inner nuclear layer (INL) and outer nuclear
layer (ONL) at 200x magnification and number of cells were
counted in an area of 100 micrometer retina length in GCL and
50 micrometer in INL and ONL.
Statistical analysis
All data are expressed as mean ± SD. Data were evaluated
by analysis of variance (ANOVA) with Tukey‘s posttests to
show differences between the groups. A p-value less than 0.05
was considered as statistical significant.
Results
Oral carnosine treatment did not affect the de-
velopment of experimental hyperglycemia but
increased retinal carnosine content in diabetic
rats
STZ-diabetic rats were orally treated with carnos-
ine (1g/kg of body weight/day, DC+C) and metabolic
parameters were compared to non-diabetic (NC) and
diabetic rats without carnosine treatment (DC). STZ-in-
duced diabetes led to stably elevated blood glucose lev-
els and significantly reduced retinal carnosine content in
DC (-31%, p<0.05 compared to NC), two weeks after
diabetes induction (Table 1). In DC+C, retinal carnosine
content was increased by 73% when compared to NC
(p<0.05) and over 1.5-fold in comparison to DC (p<0.05).
Carnosine treatment neither affected the onset or the
progression of STZ-induced hyperglycemia, nor the ces-
sation of body weight development observed in DC. As
summarized in Table 1, final body weights were signifi-
cantly reduced in DC and DC+C at 3 and 6 months of
hyperglycemia and blood glucose levels and HbA1c were
significantly elevated in both diabetic groups. Carnosine
treatment had no effect on metabolic control as body
weights, final blood glucose levels and HbA1c did not
differ between DC and DC+C (Tab. 1).
Oral carnosine treatment delayed cataract for-
mation in diabetic animals
Topical application of carnosine eye drops in the
treatment of senile and diabetic cataract is currently un-
der investigation. In this study, diabetic rats were treated
systemically by oral carnosine intake and the formation
of cataract was monitored. DC started to develop cata-
ract after 1 month of hyperglycemia (Fig. 1). After 3
months of treatment, 31% of eyes of DC displayed cata-
ract formation (10/32 lenses, p<0.05 compared to NC).
In contrast, lenses of DC+C were free of cataract for-
mation (0/18 lenses affected by cataract formation, p<0.05
vs DC) after 3 months. At 6 months of diabetes duration,
93% of the lenses of DC (28/30 lenses, p<0.05 com-
pared to NC) and 78% of the lenses of DC+C suffered
from cataract formation (14/18, p<0.05 compared to NC,
DC vs. DC+C not significant).
Carnosine treatment prevents vascular damage
in diabetic retinas
Pericyte loss and vasoregression are hallmarks of
experimental DR. In our study, retinal pericyte numbers
were reduced by 16 % (NC vs. DC: 2026 ± 136 and
1707 ± 50 cells per mm2 of capillary area, p<0.05, Fig.2B)
and vasoregression profiles were increased by 66% (NC
vs. DC: 9.2 ± 3.1 and 15.3 ± 4.8 acellular segments per
retinal area, p<0.05, Fig. 2A, C) in retinas of DC after 6
months. Carnosine treatment prevented both, loss of reti-






















296.3 ± 35.0 *
292.0 ± 32.9 *
32.8 ± 1.1 *
33.0 ± 0.8 *
13.7 ± 4.0 *
15.4 ± 2.2 *
308.2 ± 39.0 *
333.0 ± 30.5 *
33.1 ± 0.7 *
32.4 ± 2.5 *
11.2 ± 2.7 *
16.5 ± 1.7 *
Retinal Carnosine
content (μmol) (n=4) 0.74 ± 0.17 0.51 ± 0.02 * 1.28 ± 0.57 *
,#
Table 1. Metabolic data and retinal carnosine content of non-
diabetic (NC), diabetic (DC) and diabetic rats substituted with
carnosine (DC+C). Carnosine treatment did not affect the de-
velopment of experimental diabetes. Endogenous carnosine
levels are reduced in diabetic retinas and oral carnosine treat-
ment restored retinal carnosine content. *=p<0.05 compared to
non-diabetics, #=p<0.05 compared to diabetics. NC: non-dia-
betic, DC: diabetic, DC+C: diabetic with carnosine.
Fig. 1. Representative pictures of eyes of a non-diabetic (left
picture) and a diabetic rat (right picture) 1.5 months after diabe-
tes induction. Note clear lens of non-diabetic (NC) and opacity
in lens of diabetic (DC) animals.
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cells per mm2 of capillary area, p<0.05, NC vs. DC+C
not significant, Fig. 2B) and hyperglycemia induced
vasoregression (DC vs. DC+C: 15.3 ± 4.8 and 8.0 ± 3.0
acellular segments per retinal area, p<0.05, NC vs. DC+C
not significant, Fig. 2A, C). We found normal endothelial
cell numbers in retinas of NC, DC and DC+C (NC: 3317
± 268, DC: 3198 ± 142 and DC+C: 3299 ± 217 cells per
mm2 of capillary area, differences between groups not
significant, Fig. 2D) after 6 months.
Carnosine did not prevent biochemical changes
in diabetic retinas
To investigate whether carnosine treatment pro-
tected against oxidative stress in diabetic rat retinas, lev-
els of nitrotyrosine (NT) were analysed in retinal lysates
after 3 months of hyperglycemia. NT-modified proteins
were unsignificantly increased in retinas of DC when
compared to NC (+51% compared to NC, p>0.05, Fig.
3A, B) suggesting moderate increased nitrosative stress.
In retinas of DC+C, NT levels were significantly elevated
when compared to NC (+165% compared to NC, p<0.05),
but did not differ between DC and DC+C (+75% com-
pared to DC, DC vs. DC+C not significant, Fig. 3A, B).
To evaluate the effect of carnosine on AGE production
in diabetic retinas, we assessed levels of methylglyoxal
(MG)-type AGEs in retinal protein extracts after 3 months
of hyperglycemia. MG levels were significantly increased
in retinas of DC (+45% compared to NC, p<0.05, Fig.
3C, D), but not in DC+C (+25% compared to NC, p>0.05,
Fig. 3C, D) and did not differ significantly between DC
and DC+C (-14% compared to DC, DC vs. DC+C not
significant, Fig. 3C, D). Furthermore, the effect of car-
nosine treatment on hyperglycemia-induced modification
of retinal proteins by O-GlcNAc, as an indicator of hex-
osamine pathway activation was evaluated (Fig. 3E, F).
Compared with retinas of NC, O-GlcNAc protein modi-
fication was increased by 100% in retinas of DC (p>0.05
compared to NC) and 102% in retinas of DC+C (p>0.05
compared to NC, DC vs. DC+C not significant).
Carnosine treatment inhibited Ang-2
upregulation in diabetic retinas
Chronic hyperglycemia modulates the expression of
Ang-2 and VEGF, thereby inducing vascular damage in
DR. In this study, we found no differences in the expres-
sion of Ang-2 in the studied groups at 3 months of
hyperglycemia (differences between NC, DC and DC+C
not significant, Fig. 4A, B). However, Ang-2 was signifi-
cantly upregulated by 106% in retinas of DC after 6
months of hyperglycemia (p<0.05 compared to NC, Fig.
4C, D). Retinas of DC+C showed normalized Ang-2 lev-
els after 6 months of experimental diabetes (-42% com-
Fig. 2. Quantitative retinal morphometry at 6 months of hyperglycemia. Pericyte numbers (B), numbers of vasoregression
profiles (C) and endothelial cell numbers (D) were assessed in PAS-stained retinal digest preparations (A). Arrows in A indicate
vasoregression profiles. We found significant loss of pericytes (p<0.05) and increased vasoregression profiles (p<0.05) in retinas
of diabetic animals (DC) when compared to non-diabetic controls (NC). Carnosine treatment (DC+C) prevented hyperglycemia
induced pericyte loss and vasoregression. Furthermore we found normal endothelial cells numbers in all studied groups, Data
presented as mean ± SD, *=p<0.05 compared to NC, #=p<0.05 compared to DC. n=6 per group.
A
B C D
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pared to DC, p>0.05; NC vs. DC+C not significant, Fig.
4C, D). Retinal VEGF levels were significant increase in
retinas of DC compared to NC after 3 and 6 months
(+127% and +78% compared to NC, respectively, both
p<0.05 compared to NC, Fig. 4E- H). In retinas of DC+C,
VEGF levels were increased by +47% compared to NC
after 3 months of hyperglycemia (NC vs. DC+C and DC
vs. DC+C not significant, Fig. 4E, F) and significantly
elevated after 6 months (+96% NC vs. DC+C p< 0.05,
Fig. 4 G, H). After 6 months of hyperglycemia, we found
no difference in VEGF expression between DC and
DC+C (+10% compared to DC, DC vs. DC+C not sig-
nificant, Fig. 4G, H).
Carnosine treatment induced retinal Hsp27 ex-
pression in diabetic retinas
Carnosine treatment induces the expression of Hsp
in other experimental models. Therefore, we investigated
retinal protein expression levels of Hsp27 and HO-1 af-
ter 3 and 6 months. We found no changes in the expres-
sion of Hsp27 (+48% compared to NC, NC vs. DC not
significant, Fig. 5A, B) and HO-1 (+90% compared to
NC, NC: 0.28 ng/ml ± 0.17 and DC: 0.54 ng/ml ± 0.25,
NC vs. DC not significant, Fig. 5C) in retinas of DC af-
ter 3 months of hyperglycemia. However, Hsp27 expres-
sion was significantly induced over 4-fold in retinas of
DC+C when compared to NC (p<0.05 compared to NC,
Fig. 5A, B) and by 257% in comparison to DC (p<0.05
compared to DC, Fig. 5A, B). In contrast, HO-1 expres-
sion was unaffected by carnosine treatment at 3 months
of diabetes duration (+54% compared to NC, NC: 0.28
ng/ml ± 0.17 and DC+C: 0.43 ng/ml ± 0.19, NC vs. DC+C
not significant, Fig. 5C) and no difference in HO-1 ex-
pression was observed between DC and DC+C (DC:
0.54 ng/ml ± 0.25 and DC+C: 0.43 ng/ml ± 0.19, DC vs.
DC+C not significant, Fig. 5C) at this time point. After 6
months of hyperglycemia, expression of Hsp27 was in-
creased by +360% (p<0.05 compared to NC, Fig. 5D, E)
Fig. 3. Representative examples(A, C, E) and quantification (B, D, F) of Western blots of nitrotyrosine (NT) as a marker of
oxidative stress (A, B), methylglyoxal (MG)-type AGEs (C, D) and GlcNAc as a marker for hexosamine pathway activation (E, F).
Retinal protein extracts of non-diabetic (NC), diabetic (DC) and diabetic rats treated with carnosine (DC+C) were analyzed after
3 months of hyperglycemia. In retinas of DC, levels of NT, MG and GlcNAc when compared to NC (* p<0.05). Oral carnosine
treatment had no effect on hyperglycemia-induced ROS-production, AGE-formation and activation of hexosamine pathway.
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and HO-1 by +190% in DC when compared to NC (NC:
0.11 ng/ml ± 0.06 and DC: 0.33 ng/ml ± 0.16, p<0.05, Fig.
5F). In retinas of DC+C, Hsp27 and HO-1 were also
significantly increased (+230% and +212%, respectively,
both p<0.05 compared to NC, HO-1 in NC: 0.11 ng/ml ±
0.06, HO-1 in DC: 0.36 ng/ml ± 0.15 and HO-1 in DC+C:
0.36 ± 0.15, Fig. 5D- F), but carnosine treatment
showed no further induction of Hsp27 and HO-1 protein
when compared to of DC after 6 months (-28% and +7%,
respectively, both DC vs. DC+C not significant, Fig.
5D- F).
Carnosine treatment induced Hsp27 expression
in activated glial cells
Glial activation accompanies vascular defects in the
diabetic retina. In order to investigate the effect of
hyperglycemia and carnosine treatment on the activation
of retinal glial cells, immunoblots of retinal protein ex-
tracts probed against GFAP as a marker for glial cell
activation were densitometrically analyzed. After 3 months
of hyperglycemia, retinal GFAP expression was increased
by 109% in retinas of DC (p>0.05 compared to NC) and
upregulated by almost 4 fold in retinas of DC+C (p<0.05
Fig. 4. Representative examples (A,
C, E, G) and quantification (B, D, F, H)
of Western blots of Ang-2 (A-D) and
VEGF (E-H). Retinal protein extracts of
non-diabetic (NC), diabetic (DC) and
diabetic rats treated with carnosine
(DC+C) were analyzed after 3 months
(A, B, E, F) and 6 months (C, D,G, H) of
hyperglycemia. In retinas of DC, Ang-
2 expression was upregulated after 6
months of hyperglycemia and VEGF
levels were increased after 3 and 6
months. Carnosine treatment pre-
vented upregulation of Ang-2 in dia-
betic retinas at 6 months of experimen-
tal diabetes and reduced retinal VEGF
after 3 months. Values were based on
3-6 different animals per group. Data
presented as mean ± SD, * p< 0.05 com-
pared to NC, # p<0.05 compared to DC.
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Fig. 5. Illustration (A, D) and quan-
tification (B, E) of Western blots of
Hsp27 (A, B, D, E) and results ob-
tained by ELISA system for HO-1(C,
F). Retinal protein extracts of non-
diabetic (NC), diabetic (DC) and dia-
betic rats treated with carnosine
(DC+C) were analyzed after 3
months (A-C) and 6 months (D-F)
of hyperglycemia. In DC+C, Hsp27
was significantly upregulated after
3 months of hyperglycemia (A, B),
whereas Hsp27 was significantly
elevated in DC after 6 months when
compared with non-diabetics con-
trols (D, E). All diabetic retinas
showed significantly increased lev-
els of HO-1 after 6 months (F). Car-
nosine treatment had no effect on
hyperglycemia-induced HO-1 ex-
pression in diabetic retinas. n=4-6
per group. Data presented as mean
± SD, * p< 0.05 compared to NC, #
p<0.05 compared to DC. GAPDH:
protein loading control.
compared to NC, DC vs. DC+C not significant, Fig. 6A,
B) when compared to NC. After 6 months of
hyperglycemia, GFAP expression was slightly increased
in retinas of DC (+77% compared to NC, p>0.05, Fig.
6C, D) and upregulated by 80% in retinas of DC+C
(p>0.05 compared to NC, DC vs. DC+C not significant)
as shown in Figure 6 C and D.
In order to localize Hsp27 upregulation in the retina,







Fig. 6. Illustration (A, C) and quan-
tification (B, D) of Western blots of
GFAP as a marker of glial cell activa-
tion. Retinal protein extracts of non-
diabetic (NC), diabetic (DC) and dia-
betic rats treated with carnosine
(DC+C) were analyzed after 3
months (A, B) and 6 months (C, D)
of hyperglycemia. As shown in Fig.
6 A and B, carnosine treatment led
to a significant upregulation of
GFAP in 3 months diabetic retinas.
In retinas of DC, GFAP was slightly
induced after 3 months (A, B), but
significantly upregulated after 6
months of hyperglycemia (C, D).
n=4-6 per group. Data presented as
mean ± SD,* p< 0.05 compared to






as a glial marker and DAPI as nuclear marker. As de-
picted in Figure 7, carnosine induced upregulation of
Hsp27 at 3 months of hyperglycemia was found in
astrocytes and Muller cells throughout the entire retina.
In accordance to our Western blot results, Hsp27 ex-
pression was slightly induced in DC after 3 months of
hyperglycemia and highly expressed in retinal astrocytes
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Fig. 7. Immunoflurescence staining of vertical paraffin sec-
tions of non-diabetic (NC), diabetic (DC) and diabetic rats
treated with carnosine (DC+C) for GFAP (red) and Hsp27 (green)
and DAPI as a nuclear marker (blue). Carnosine induced Hsp27
upregulation in GFAP-positive astrocytes and in Muller cells
throughout the entire retina after 3 and 6 months, whereas
retinas of DC showed upregulation of Hsp27 in GFAP-positive




Fig. 8. Illustration (A) and quantification (B) of neuronal
changes in PAS-stained paraffin sections of non-diabetic (NC),
diabetic (DC) and diabetic rats treated with carnosine (DC+C)
after 3 months of hyperglycemia. Numbers of cell nuclei were
counted in each nuclear layer of the retina (GCL: ganglion cell
layer, INL: inner nuclear layer, ONL: outer nuclear layer, white
bars: NC, black bars: DC and grey bars: DC+C). In retinas of
DC, numbers of cells in the GCL were significantly reduced (B).
In retinas of DC+C, thickness and cell numbers of ONL are
significantly reduced (A, B). n=3-4 per group. * p< 0.05 com-
pared to NC, # p<0.05 compared to DC. Original magnification
400x.
Carnosine treatment induced loss of photorecep-
tor cells
Neuronal cell loss has been observed as an early
abnormality in diabetic retinas. The effect of experimen-
tal diabetes and oral carnosine supplementation on neu-
ronal cells of the retina in this study was examined in
PAS and hematoxylin stained paraffin section. We found
a significant reduction of ganglion cell nuclei in retinas of
DC at 3 months (-18% compared to NC, NC: 8.8 cell
nuclei/area ± 0.5 and DC: 7.2 cell nuclei/area ± 0.6, p<0.05,
Fig. 8A, B) and a significant reduction in cell numbers
and thickness of the outer nuclear layer in retinas of DC+C
at 3 months of diabetes duration (-61% compared to NC
and -59% compared to DC, NC: 100.2 cell nuclei/area,
DC: 94.5 cell nuclei/area ± 7.6 and DC+C: 38.6 cell nu-
clei/area ± 31.8, p<0.05 compared to NC and DC, Fig. 8
A, B).
Discussion
Growing evidence indicate a protective potential of
carnosine in the treatment of diabetic complications. In
this study, carnosine was tested in the prevention of ex-
perimental DR. We demonstrate that oral carnosine treat-
ment delays the onset of hyperglycemia induced cata-
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ract formation and prevents diabetes associated retinal
vascular damage. These protective effects of carnosine
were associated with induced expression of Hsp27 in
activated retinal glial cells and prevention of
hyperglycemia-induced upregulation of Ang-2. Interest-
ingly, we could not confirm the antioxidative and
antiglycating capacity of carnosine in this in vivo study.
Furthermore, we show that high dose carnosine treat-
ment led to a severe reduction in the number retinal pho-
toreceptor cells.
In this study, carnosine completely prevented
hyperglycemia-induced pericyte loss and vasoregression,
demonstrating that carnosine directly or indirectly affects
key steps in the cascade of pathological events in both,
endothelial cells and pericytes. Retinal pericyte loss and
the formation of non-perfused acellular capillaries are the
cell-biological consequence of chronic hyperglycemic
damage [2, 5]. A great body of evidence demonstrate
that hyperglycemia induces an increased production of
ROS, increases the formation of AGEs, which accumu-
late in microvascular cells in vivo and activates biochemi-
cal pathways, such as the hexosamine pathway [36]. On
one side, these biochemical changes directly damage reti-
nal cells by disturbed energy metabolism and modifica-
tion of important intra- and extracellular proteins [37, 38].
On the other side, these highly active metabolic interme-
diates deregulate the expression of important angiogenic
and inflammatory cytokines thereby indirectly damage
retinal cells [39-41].
We recently provided evidence that upon direct cell
toxicity of hyperglycemia upregulation of Ang-2 is impli-
cated in diabetic pericyte loss and retinal vasoregression.
Intravitreal injection of recombinant Ang-2 leads to peri-
cyte loss and vasoregression in non-diabetic retinas and
reduction of functional Ang-2 gene dose in a transgenic
approach prevents vascular damage in diabetic retinas
[42-44]. Consistent with previous observations, Ang-2 was
significantly upregulated in diabetic retinas in this study.
Interestingly, carnosine treatment normalized Ang-2 lev-
els in diabetic retinas and this was associated with vas-
cular protection. A number of factors have been described
so far to be involved in the regulation of Ang-2, including
hypoxia, tissue ischemia and growth factors such as VEGF
[45-47]. It has been recently demonstrated that increased
glucose flux in microvascular endothelial cells upregulates
Ang-2 gene expression by increased modification of tran-
scription complexes by MG and O-linked GlcNAc, but
the specific mechanisms and localization of early Ang-2
upregulation in the diabetic retina are unclear [40]. Car-
nosine treatment neither affected protein modification by
MG-type AGEs nor by O-GlcNAc modification in dia-
betic retinas. Therefore, it is unlikely that carnosine treat-
ment prevented Ang-2 upregulation in diabetic retinas due
to its biochemical properties.
Carnosine is considered to be one of the most abun-
dant naturally occurring antioxidant in the brain and its
expression has been documented in specialized receptor
neurons, neural progenitor cells and in glial cells distrib-
uted throughout the whole brain and spinal cord [48]. The
exact function of carnosine in the CNS remains unknown,
although a neuroprotective and neuromodulatory func-
tion has been advanced. In the retina, expression and
function of carnosine and related dipeptides have been
studied in less detail. The presence of carnosine has been
demonstrated in photoreceptors and bipolar cells of am-
phibian retina, in a few ganglion cells and in endfoot proc-
esses of retinal Mueller cells [25-27]. Interestingly, car-
nosine treatment affected unspecified cells of the gan-
glion cell layer, Mueller cells throughout the entire retina
and neurons of the outer retinal layers, suggesting a spe-
cific susceptibility of these cells to carnosine. However,
glial cell activation indicated by upregulation of GFAP
and Hsp are unspecific reactions occurring in several
models of retinal damage, including DR [49, 50]. There-
fore, carnosine-induced upregulation of Hsp27 in acti-
vated Mueller and glial cell after 3 months might also be
an unspecific consequence to artificially increased car-
nosine levels and consequentially increased cellular stress.
As an important effect of the treatment, we demon-
strate that cells of the outer nuclear layer were affected
by carnosine treatment. Carnosine treated animals
showed loss of photoreceptor cells. As mentioned, car-
nosine and related dipeptides localize to retinal photore-
ceptor cells and bipolar cells in various species and the
appearance of carnosine-like immunoreactivity during
retinal development is associated with the onset of visual
function. In addition, a role as a neurotransmitter or
neuromodulator in sensory systems has been proposed
[25, 27, 51]. Therefore it seems likely that excessive supply
of carnosine in this study led to misbalanced cross-talk of
retinal neuronal cells and possibly even to cell damage in
outer retinal neurons. Importantly, patients with
homocarnosinosis, an inherited disorder, characterized by
elevated levels of homocarnosine, carnosinuria and
carnosinase deficiency suffer from photoreceptor degen-
eration [52]. In addition, there is increasing evidence that
diabetic patients with outer retinal retinitis degenerative
disorder pigmentosa have a reduced risk of the develop-
ment of incipient DR [53, 54]. Likewise, it has been dem-
onstrated that loss of the outer retina reduces the sever-
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ity of experimental DR [55]. Therefore, we have to ac-
knowledge that it might also be possible that the protec-
tive effect of carnosine found in this study is mediated by
the influence of carnosine on non-vascular cells.
In conclusion, oral carnosine treatment in diabetic
rats delays diabetic cataract formation and protects reti-
nal capillaries from hyperglycemic damage. In parallel,
carnosine treatment activates retinal glial cells and in-
duces loss of outer retinal cell nuclei. Based on these
findings it is obvious that further research is necessary to
understand the role of carnosine in rodent and human
retina and the potential use of carnosine in the treatment
of DR and other diseases.
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